Hemophilia A – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

Hemophilia A is an x-linked genetic disorder characterized by the deficiency of factor VIII. the liver is the predominant source of factor VIII, which is then secreted and circulated in the bloodstream in an inactive form in a complex with von Willebrand factor. Several other tissues produce factor VIII, including the endothelium. Factor IX is produced entirely by the liver. Chronic hemarthroses are one of the most common long-term complications of hemophilia. Intra-articular bleeding may resolve on its own or with treatment in an acute case. However, many patients will experience recurrent bleeding and develop single or multiple target joints that are often painful and restrict their daily activity. Common sites are the knee, elbow, and ankle. Over time, chronic synovitis and chronic hemarthroses can result in degenerative joint disease, osteoarthritis, and osteophyte formation.

In the United States, most people with hemophilia are diagnosed at a very young age, Hemophilia A affects 1 in 5,000 male births.

The prevalence varies among different parts of the world, with a range of 5.4 - 14.5 cases per 100,000 males. In the United States, the prevalence of hemophilia A is estimated to be 20.6 cases per 100,000 males.

 

The competitive landscape of Hemophilia A includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Hemophilia A across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hemophilia A Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Hemophilia A – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ASC618            ASC Therapeutics         Phase 2

2          PF-06741086    Pfizer    Phase 3

3          OCTA101         Octapharma      Phase 2

4          SPK-8011         Spark Therapeutics       Phase 1/2

5          Valoctocogene Roxaparvovec    BioMarin Pharmaceutical            Phase 2

6          rVIII-SingleChain           CSL Behring     Phase 3

7          Emicizumab      Hoffmann-La Roche      Phase 3

8          BAX 855           Baxalta now part of Shire           Phase 2

9          BAY2599023 (DTX201) Bayer   Phase 2

10        Concizumab      Novo Nordisk A/S          Phase 2

Continued